Opexa Therapeutics Announces Tcelna(TM) as New Brand Name for MS Therapy - MarketWatch
Cautionary Statement Relating to Forward - Looking Information for the Purpose of "Safe Harbor" Provisions of the Private Securities Litigation Reform Act 1995.
press release
May 21, 2012, 8:30 a.m. EDT
Opexa Therapeutics Announces Tcelna(TM) as New Brand Name for MS Therapy
THE WOODLANDS, Texas, May 21, 2012 (BUSINESS WIRE) -- Opexa Therapeutics, Inc. OPXA , a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna(TM).
The product, previously known as Tovaxin(R), will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
The product, previously known as Tovaxin(R), will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
"Opexa has worked diligently in the optimization of its overall manufacturing process and clinical development program while concentrating its efforts in the SPMS indication. The rebranding of our lead product as Tcelna encompasses these advancements and our continued dedication to make a difference in the treatment of MS," commented Neil K. Warma, President and Chief Executive Officer of Opexa.
The name Tcelna (pronounced Te-SELL-nuh) reflects the T-cell derivation of the product. Opexa has requested a registered trademark for the new brand name.
About Opexa
Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS). The Company's leading therapy, Tcelna(TM), a personalized cellular immunotherapy treatment, is in clinical development targeting both Secondary Progressive and Relapsing Remitting MS.
Tcelna is derived from T-cells isolated from peripheral blood, expanded ex vivo and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.
For more information, visit the Company's website at www.opexatherapeutics.com .
SOURCE: Opexa Therapeutics, Inc.
Neil K. Warma
Opexa Therapeutics, Inc.
President & CEO
281-775-0600
nwarma@opexatherapeutics.com
No comments:
Post a Comment